Showing posts with label EPO. Show all posts
Showing posts with label EPO. Show all posts

Thursday, February 25, 2016

Equine Erythropoietin (EPO) Do-It-Yourself ELISA, ≤10 Plates

The Equine Erythropoietin Do-It-Yourself ELISA contains capture antibody, protein standard, and detection antibody for development of a Equine EPO ELISA. The antibodies have been determined to function in an ELISA with the standard provided. Optimal buffers, concentrations, incubation times, incubation temperatures, and methods for the ELISA have not been determined.

Erythropoietin (EPO) is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Erythropoietin has its primary effect on red blood cell progenitors and precursors by promoting their survival through protecting these cells from apoptosis. It is the primary erythropoietic factor that cooperates with various other growth factors (e.g., IL-3, IL-6, glucocorticoids, and SCF) involved in the development of erythroid lineage from multipotent progenitors. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers.


Wednesday, June 17, 2015

EPO and Erythropoiesis


The orchestration of a complex, hierarchical process like erythropoiesis requires the precise coordination of a host of cellular factors that work either in concert or at distinct stages of the process, to regulate effective and sufficient formation of RBCs. The principal regulator of erythropoiesis is Erythropoietin (EPO), a heavily glycosylated protein belonging to the class I cytokine family (Jelkmann, 2004). EPO exerts its effects on erythropoiesis by binding to and activating the EPOreceptor (EpoR), a high affinity receptor that is predominantly expressed on the surface of immature erythroid cells. EpoR belongs to the type I cytokine receptor family and exists as a homodimer. Upon ligand binding, EpoR, which lacks intrinsic catalytic activity, undergoes a conformational change and associates with Janus Kinase 2 (JAK2). JAK2 phosphorylates the ligand-activated EpoR, generating multiple docking sites for signaling molecules, and leading to activation of several signal transduction pathways (Watowich, 2011). While one of the earliest studied signaling pathways activated through the EPO-EpoR cascade is the Janus Kinase and Signal Transducer and Activator of Transcription (JAK/STAT) pathway, phosphorylated EpoR induces activation of other cellular signaling cascades including the mitogen-activated protein kinase/extracellular signal-related kinase (MAPK/ERK) and the phosphatidylinositol 3-kinase /protein kinase B (PI-3K/AKT) pathways (Ingley et al., 2004). These pathways impact erythropoiesis by temporally regulating transcription of genes involved in survival, differentiation, and cell proliferation depending on the stage of erythroid maturation. For example, survival signals are provided to CFU-E cells, the most EPO-sensitive cells amongst the erythroid progenitors, as well as to erythroblasts. The importance of EPO-EpoR signaling in erythropoiesis has been demonstrated by EPO-null and EpoR-null mouse models, which are both embryonically lethal, owing to a lack of erythropoiesis in the fetus (Wu et al., 1995). While the EPO-EpoR signaling axis serves as the central hub for erythropoiesis regulation, several other molecular signals, both extrinsic and intrinsic, are involved and serve to further fine-tune the progression of the multi-faceted process of erythropoiesis (Ingley, 2012; Ingley et al., 2004; Kuhrt and Wojchowski, 2015). more... 

Check out Kingfisher Biotech's growing portfolio of EPO products, including recombinant proteins, polyclonal antibodies and ELISA Kits.

Thursday, March 19, 2015

Swine Erythropoietin Do-It-Yourself ELISA

Erythropoietin (EPO) is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Erythropoietin has its primary effect on red blood cell progenitors and precursors by promoting their survival through protecting these cells from apoptosis. It is the primary erythropoietic factor that cooperates with various other growth factors (e.g., IL-3, IL-6, glucocorticoids, and SCF) involved in the development of erythroid lineage from multipotent progenitors. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It can increase iron absorption by suppressing the hormone hepcidin.

The Swine Erythropoietin (EPO) Do-It-Yourself ELISA contains capture antibody, standard, and detection antibody for development of a Swine EPO ELISA. The antibodies have been determined to function in an ELISA with the standard provided. Optimal buffers, concentrations, incubation times, incubation temperatures, and methods for the ELISA have not been determined. A working knowledge of ELISA is strongly recommended. The quantities of components provided are not matched. Components may also be purchased separately. 

ComponentUsageQuantityCatalog #
Anti-Swine Erythropoietin PAbCapture Antibody100 µgKP1003S-100
Biotinylated Anti-Swine Erythropoietin PAb Detection Antibody50 µgKPB1004S-050
Swine Erythropoietin ProteinStandard5 µgRP0938S-005

Thursday, February 19, 2015

Canine, Equine, and Swine Erythropoietin Recombinant Proteins

Erythropoietin (EPO) is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Erythropoietin has its primary effect on red blood cell progenitors and precursors by promoting their survival through protecting these cells from apoptosis. It is the primary erythropoietic factor that cooperates with various other growth factors (e.g., IL-3, IL-6, glucocorticoids, and SCF) involved in the development of erythroid lineage from multipotent progenitors. Erythropoietin has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It can increase iron absorption by suppressing the hormone hepcidin. EPO is highly glycosylated, with half-life in blood around five hours. The half-life of EPO may vary between endogenous and various recombinant versions. Additional glycosylation or other alterations of EPO via recombinant technology have led to increased stability in blood. EPO binds to the erythropoietin receptor on the red cell progenitor surface and activates a JAK2 signaling cascade. Erythropoietin receptor expression is found in a number of tissues, such as bone marrow and peripheral/central nervous tissue. In the bloodstream, red cells themselves do not express erythropoietin receptor, so cannot respond to EPO. However, indirect dependence of red cell longevity in the blood on plasma erythropoietin levels has been reported, a process termed neocytolysis. Kigfisher Biotech's recombinant Erythropoietin proteins are intended for use in animal model and animal health research and can be used in cell culture, as an EPO ELISA Standard, and as a Western Blot Control. Canine, equine, and swine EPO recombinant proteins are now available from Kingfisher Biotech.

Kingfisher Biotech, Inc. is committed to accelerating basic veterinary research and human disease research done in animal models by developing and commercializing research reagents specific for a variety of species, including bovine, canine, caprine, chicken, dolphin, equine, feline, guinea pig, hamster, human, mouse, ovine, rabbit, rat, swine, and turkey. We will continue to add species as our customer request specific reagents for their research. Currently, we offer over 1200 recombinant proteins, polyclonal antibodies, monoclonal antibodies and ELISA kits for animal health and animal model research. Our products are primarily cytokines, chemokines, interferons, and growth factors. Our product development queue is filled mainly by customer requests. If there is a product that you are looking for and can't find, please send us an email.